Business context and reporting period
The supplied filing is ADVENTRX Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2012—not a filing under the name Savara Inc. The filing describes ADVENTRX as a development-stage biopharmaceutical company focused primarily on ANX-188, a candidate for sickle cell disease. It had no product sales or revenue in either 2012 reporting period.
Financial performance and position
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| R&D expense | $2.11 million | $1.34 million | $4.32 million | $1.95 million |
| SG&A expense | $1.87 million | $1.82 million | $3.92 million | $3.40 million |
| Operating loss | $4.22 million | $4.41 million | $8.39 million | $7.40 million |
| Net loss | $4.21 million | $4.39 million | $8.36 million | $7.35 million |
| Basic and diluted loss per share | $0.09 | $0.17 | $0.18 | $0.30 |
With no revenue, a revenue margin is not applicable. Net cash used in operating activities was $7.35 million in the first half, versus $6.98 million a year earlier. Cash and cash equivalents were $29.96 million and short-term investments were $13.12 million at June 30, totaling approximately $43.07 million. Current assets were $44.29 million and current liabilities $2.49 million. Total liabilities were $5.10 million, including a $2.61 million deferred tax liability; the balance sheet reports no outstanding debt balance.
Material changes versus prior period
- First-half R&D expense rose 121% to $4.32 million, principally from manufacturing and nonclinical costs for ANX-188 and ANX-514, higher personnel costs, and increased clinical consulting.
- First-half net loss increased by approximately $1.02 million. Lower transaction-related expenses—$0.09 million versus $2.03 million—partly offset higher R&D and SG&A.
- Q2 net loss narrowed modestly, while loss per share improved substantially year over year; weighted-average shares increased to 47.72 million from 26.25 million in Q2 2011, affecting comparability.
- Cash and equivalents declined $13.61 million from year-end 2011, partly reflecting operating cash use and purchases of certificates of deposit that increased short-term investments.
Outlook, commentary and risks
- Management expected cash, cash equivalents and short-term investments at quarter-end to fund the currently planned operating level for at least 12 months, but said additional capital would be needed to support operations over time. Financing may not be available on acceptable terms or at all.
- The company planned to initiate an ANX-188 Phase 3 study in 2012, targeting 350–400 subjects at 30–40 sites, alongside smaller studies. Trial design and clinical-trial-material manufacturing were ongoing; timing, cost, recruitment, safety, efficacy and regulatory approval remained uncertain.
- ANX-514 clinical studies were not planned in the foreseeable future, and significant manufacturing-development investment had stopped. The company was conducting animal studies and might seek a third-party funder, partner, buyer or licensee; it could discontinue the program.
- A $0.30 million impairment charge was recorded in Q2 for ANX-514 manufacturing equipment following the decision to stop significant manufacturing-development investment.
- The company relied on third-party manufacturers and research organizations and identified clinical, regulatory, funding, supply, market-acceptance, intellectual-property and listing-compliance risks. Ownership changes could restrict use of tax-loss and research-credit carryforwards.
- Potential warrant exercises could provide additional funds, but proceeds are not assured and exercise would depend on holder decisions and contractual limits. The company reported 17.42 million warrants outstanding at June 30.
Important facts for investors to verify
- Confirm the issuer identity: this filing names ADVENTRX Pharmaceuticals, Inc., despite the request identifying Savara Inc.
- Check subsequent filings for whether the planned ANX-188 Phase 3 study began, its final design and enrollment, and any regulatory or clinical developments.
- Track cash burn, cash plus investments, and any new financing; the 12-month runway statement applies to planned operations and is subject to change.
- Review warrant terms, exercises and expirations, and the potential dilution from outstanding warrants and acquisition-related milestone shares.
- Monitor ANX-514’s status and any further impairment, partnering or discontinuation decisions.